Economic Value Added
Suwon Pharmaceuticals invests heavily in research and development (R&D), although it must currently treat its R&D expenditures as expenses for financial accounting purposes. To encourage investment in R&D, Suwon evaluates its division managers using EVA. The company adjusts accounting income for R&D expenditures by assuming these expenditures create assets with a two year life. That is, the R&D expenditures are capitalized and then amortized over two years.
BK division of Suwon shows after-tax income of $2.5 million for year 2. R&D expenditures in year 1 amounted to $1 million and in year 2, R&D expenditures were $1.6 million. For purposes of computing EVA, Suwon assumes all R&D expenditures are made at the beginning of the year. Before adjusting for R&D, BK division shows assets of $10 million at the beginning of year 2 and current liabilities of $200,000. Suwon computes EVA using divisional investment at the beginning of the year and a 12 percent cost of capital.
Required
Compute EVA for BK division for year 2.
Already registered? Login
Not Account? Sign up
Enter your email address to reset your password
Back to Login? Click here